COMMUNIQUÉS West-GlobeNewswire

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
01/10/2026
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI [...]
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
01/10/2026
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook [...]
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
01/10/2026
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program OCALA, Fla., Oct. 01, 2026 (GLOBE [...]
Doheny Eye Institute Experts to Share Groundbreaking Insights at the American Academy of Ophthalmology 2026 Annual Meeting
01/10/2026
Doheny-UCLA clinicians will participate in more than 30 educational sessions, scientific papers and posters covering retinal disease, glaucoma, pediatric ophthalmology and other areas of eye care PASADENA, Calif., Oct. [...]
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities
01/10/2026
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across [...]
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
01/10/2026
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀ D-PLEX₁₀₀ NDA [...]
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
01/10/2026
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
01/10/2026
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with [...]
Crohn et Colite Canada investit 1,5 million de dollars dans la recherche sur les MII et les soins futurs
01/10/2026
Quatre équipes de recherche canadiennes étudieront de nouvelles approches pour comprendre, traiter et prévenir la maladie de Crohn et la colite ulcéreuse TORONTO, 01 oct. 2026 (GLOBE NEWSWIRE) -- Le nombre de personnes [...]
Crohn’s and Colitis Canada Invests $1.5 Million to Advance IBD Research and Future Care
01/10/2026
Four Canadian research teams will investigate new approaches to understanding, treating and preventing Crohn’s disease and ulcerative colitis TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- As Canada’s inflammatory bowel [...]
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
01/10/2026
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by [...]
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
01/10/2026
Press release – No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and [...]
Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients
01/10/2026
A single dose of NovoBioJect increased the active form of methotrexate inside patients' immune cells by 38%, a first step toward a potential next-generation first-line treatment for rheumatoid arthritis First clinical [...]
HealthEdge Launches Unified AI-Powered Platform to Guarantee Financial Outcomes for Health Plans
01/10/2026
Unified platform combines technology, implementation and operational expertise to reduce administrative costs, lower transformation risk and drive continuous performance improvement BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE [...]
Government of Saskatchewan proclaims October Health Literacy Month
01/10/2026
SASKATOON, Saskatchewan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- You trust health information to help you make important decisions. But when medical terms are unfamiliar, information is difficult to find, or advice seems to [...]
Michigan Contact Lens Opens 1-800-DRY-EYES Center in Expanded Southfield Facility
01/10/2026
One year after relocating from Oak Park and nearly tripling its floor space, the specialty practice has opened a dedicated center for severe dry eye alongside two stations for teaching patients to handle scleral lenses [...]
Bloom Healthcare Brings Its Proven In-Home Care Model to Dallas-Fort Worth Seniors
01/10/2026
Home-based geriatric care model brings personalized primary care to seniors across the region DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bloom Healthcare , a passionate team of medical providers specializing in in-home [...]
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10/2026
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had [...]
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
01/10/2026
LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]

Pages